Aspira pathlab & Diagnostics Limited has formally notified the Bombay Stock Exchange regarding its regulatory status under SEBI's Large Corporate framework for the financial year 2025-2026. The company confirmed that it does not meet the criteria to be classified as a Large Corporate entity, thereby exempting it from specific annual disclosure requirements.

Regulatory Compliance Confirmation

On April 15, 2026, the company's Chief Financial Officer, Balkrishna Talawadekar, submitted an official communication to BSE confirming the company's non-qualification for Large Corporate status. The confirmation was made in accordance with SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which establishes the regulatory framework for Large Corporate entities.

Disclosure Requirements Impact

As a consequence of not meeting the Large Corporate criteria, Aspira Pathlab & Diagnostics Limited is not required to comply with the annual disclosure requirements specified in Annexure B2 of the referenced SEBI circular. These disclosure requirements typically pertain to fund raising activities through the issuance of debt securities by Large Corporate entities.

The company's confirmation ensures compliance with SEBI's regulatory framework while clarifying its exemption status from specific disclosure obligations that apply only to entities classified as Large Corporates under the established criteria.

Company Information

Aspira Pathlab & Diagnostics Limited operates as a fully integrated laboratory services provider in India. The company maintains its registered office at Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086, with its corporate office located at 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086.

Aspira pathlab & Diagnostics Limited has formally notified BSE Limited of its non-applicability under the Large Corporate framework as defined by SEBI regulations. The Mumbai-based diagnostic services company submitted its compliance confirmation on April 15, 2026, addressing requirements under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144.

Regulatory Compliance Status

The company confirmed its status as of March 31, 2026, through a detailed submission to the Corporate Relations Department of BSE Limited. Chief Financial Officer Balkrishna Talawadekar signed the compliance document, ensuring adherence to regulatory disclosure requirements.

Financial Position Details

The company's financial status as of March 31, 2026, demonstrates its position outside the Large Corporate classification criteria:

SEBI Framework Implications

Under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, companies meeting specific criteria must comply with enhanced regulations for debt securities issuance. Aspira Pathlab's confirmation indicates it falls outside these parameters, exempting it from the framework's requirements.

Company Background

Aspira Pathlab & Diagnostics Limited operates as a fully integrated diagnostic laboratory service provider. The company maintains its registered office in Ghatkopar West, Mumbai, and positions itself as India's first fully integrated lab facility. The organization provides comprehensive diagnostic services under the tagline "Predict • Prevent • Protect."

Regulatory Documentation

The company submitted Annexure A as required under the SEBI circular, providing complete details of its corporate structure and financial position. This documentation serves as official confirmation of its non-Large Corporate status and ensures compliance with regulatory disclosure obligations for the assessment period ending March 31, 2026.